Safi Biotherapeutics Lands $4.7M Defense Award to Push Manufactured Blood Toward First Trial
Safi Biotherapeutics drew a $4.7 million Defense Health Program extension, lifting its non-dilutive U.S. funding past $27 million ahead of a planned 2027 IND filing for manufactured red blood cells.